<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3900">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04575584</url>
  </required_header>
  <id_info>
    <org_study_id>4482-001</org_study_id>
    <secondary_id>2020-003367-26</secondary_id>
    <secondary_id>MK-4482-001</secondary_id>
    <secondary_id>PHRR201210-003189</secondary_id>
    <nct_id>NCT04575584</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)</brief_title>
  <official_title>A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Hospitalized Adults With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the safety, tolerability and efficacy of molnupiravir (MK-4482)&#xD;
      compared to placebo. The primary hypothesis is that molnupiravir is superior to placebo as&#xD;
      assessed by the rate of sustained recovery through Day 29.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2020</start_date>
  <completion_date type="Anticipated">December 18, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 17, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-to-sustained recovery</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>Sustained recovery is defined as: the participant is alive and not hospitalized; or the participant is alive and medically ready for discharge as determined by the investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with an adverse event (AE)</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who discontinued study intervention due to an AE</measure>
    <time_frame>Up to 6 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with all-cause mortality</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>All-cause mortality is death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary score on a scale</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>Pulmonary score is a score on an ordinal scale which focuses on respiratory sequalae based on oxygen requirements using 7 mutually exclusive categories. The score ranges from 1 to 7 with a higher score indicating more severe respiratory sequalae.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary+ score on a scale</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>Pulmonary+ score is a score on an ordinal scale which is a 7-category assessment that captures the range of disease severity, including coagulation-related complications and respiratory dysfunction. The score ranges from 1 to 7 with a higher score indicating more severe sequalae.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Early Warning Score on a scale</measure>
    <time_frame>End of Treatment (EOT) (Up to 6 days)</time_frame>
    <description>The National Early Warning Score assesses a participant's degree of illness as assessed by clinical risk prediction categories for poor clinical outcomes including mortality within 24 hours of a set of vital sign measurements. There are 7 physiological parameters, of which 6 are assigned a point value ranging from 0 to 3, and 1 is assigned a point value ranging from 0 to 2. The total aggregate score may range from 0 to 20 with an increasing aggregate score indicating increasing clinical risk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO 11-point outcomes score on a scale</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 to 10 with higher score indicating clinical progression.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">1300</enrollment>
  <condition>Coronavirus Disease (COVID-19)</condition>
  <arm_group>
    <arm_group_label>Part 1: Molnupiravir 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Molnupiravir 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Molnupiravir 800 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Molnupiravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Molnupiravir (dose to be selected) administered orally every 12 hours for 5 days (10 doses total)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Molnupiravir</intervention_name>
    <description>Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)</description>
    <arm_group_label>Part 1: Molnupiravir 200 mg</arm_group_label>
    <arm_group_label>Part 1: Molnupiravir 400 mg</arm_group_label>
    <arm_group_label>Part 1: Molnupiravir 800 mg</arm_group_label>
    <arm_group_label>Part 2: Molnupiravir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)</description>
    <arm_group_label>Part 1: Placebo</arm_group_label>
    <arm_group_label>Part 2: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has documentation of polymerase chain reaction (PCR)-confirmed severe acute&#xD;
             respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with sample collection ≤ 10&#xD;
             days prior to the day of randomization. PCR is the preferred method; however other&#xD;
             diagnostic methods are allowed if authorized by use in the country&#xD;
&#xD;
          -  Had initial onset of signs/symptoms attributable to COVID-19 for ≤10 days prior to the&#xD;
             day of randomization and ≥1 sign/symptom attributable to COVID-19 present at&#xD;
             randomization&#xD;
&#xD;
          -  Requires medical care in the hospital for ongoing clinical manifestations of COVID-19&#xD;
             (not just for public health or quarantine purposes)&#xD;
&#xD;
          -  Has mild, moderate, or severe COVID-19&#xD;
&#xD;
          -  Is willing and able to take oral medication&#xD;
&#xD;
          -  Males agree to the following during the intervention period and for at least 90 days&#xD;
             after the last dose of study intervention: Refrain from donating sperm; and either&#xD;
             abstain from heterosexual intercourse as their preferred and usual lifestyle&#xD;
             (abstinent on a long term and persistent basis) and agree to remain abstinent; or must&#xD;
             agree to use contraception&#xD;
&#xD;
          -  Females are not pregnant or breastfeeding, and at least one of the following&#xD;
             conditions applies: Is not a woman of child bearing potential (WOCBP); or is a WOCBP&#xD;
             and using a contraceptive method that is highly effective (a low user dependency&#xD;
             method OR a user dependent method in combination with barrier method), or be abstinent&#xD;
             from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a&#xD;
             long-term and persistent basis) for 28 days from the start of study intervention; a&#xD;
             WOCBP must have a negative highly sensitive pregnancy test (serum test is required)&#xD;
             within 24 hours before the first dose of study intervention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has critical COVID-19 with any of the following: respiratory failure (including&#xD;
             endotracheal intubation and mechanical ventilation, oxygen delivered by high-flow&#xD;
             nasal cannula (flow rates &gt;20L/min with fraction of delivered oxygen &gt;= 0.5),&#xD;
             noninvasive positive pressure ventilation, or extracorporeal membrane oxygenation&#xD;
             (ECMO))&#xD;
&#xD;
          -  Is on dialysis or has reduced estimated glomerular filtration rate (eGFR) &lt;30&#xD;
             mL/min/1.73m^2 by the Modification of Diet in Renal Disease (MDRD) equation&#xD;
&#xD;
          -  Has any of the following conditions: human immunodeficiency virus (HIV) with a recent&#xD;
             viral load &gt;50 copies/mL or cluster of differentiation 4 (CD4) &lt;200 cell/mm^3;&#xD;
             chemotherapy required within 6 weeks before randomization; a neutrophilic granulocyte&#xD;
             absolute count &lt;500/mm^3; autologous or allogeneic hematopoietic stem cell transplant&#xD;
             recipient&#xD;
&#xD;
          -  Has history of Hepatitis B or Hepatitis C infection with any of the following: 1)&#xD;
             cirrhosis 2) end-stage liver disease 3) hepatocellular carcinoma 4) aspartate&#xD;
             aminotransferase (AST) and/or alanine aminotransferase (ALT) &gt; 3 times the upper limit&#xD;
             of normal at screening&#xD;
&#xD;
          -  Has a history of acute pancreatitis within 3 months prior to randomization or a&#xD;
             history of chronic pancreatitis&#xD;
&#xD;
          -  Is taking or is anticipated to require any prohibited therapies&#xD;
&#xD;
          -  Is unwilling to abstain from participating in another interventional clinical trial&#xD;
             through Day 29 with an investigational compound or device, including those for&#xD;
             COVID-19 therapeutics&#xD;
&#xD;
          -  Is anticipated to require transfer to a non-study hospital within 72 hours&#xD;
&#xD;
          -  Has a baseline heart rate of &lt; 50 beats per minute at rest&#xD;
&#xD;
          -  Has a platelet count &lt;100,000/μL or received a platelet transfusion in the 5 days&#xD;
             prior to randomization&#xD;
&#xD;
          -  Has hypersensitivity or other contraindication to any of the components of the study&#xD;
             interventions as determined by the investigator&#xD;
&#xD;
          -  Has any condition for which, in the opinion of the investigator, participation would&#xD;
             not be in the best interest of the participant or that could prevent, limit, or&#xD;
             confound the protocol-specified assessments including but not limited to: participants&#xD;
             who are not expected to survive longer than 48 hours after randomization or&#xD;
             participants who are expected to require mechanical ventilation within 48 hours after&#xD;
             randomization or participants with a recent history of mechanical ventilation or&#xD;
             participants with conditions that could limit gastrointestinal absorption of capsule&#xD;
             contents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kaiser Foundation Hospital - South Bay ( Site 1832)</name>
      <address>
        <city>Harbor City</city>
        <state>California</state>
        <zip>90710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>800-823-2020</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center ( Site 1822)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>919-971-6441</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center ( Site 1809)</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>916-734-3815</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Florida ( Site 1810)</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>352-294-5481</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wellstar Kennestone Hospital ( Site 1801)</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>770-429-0083</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Loretto Hospital ( Site 1838)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60644</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>773-716-6813</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>LSU-HSC Shreveport ( Site 1824)</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>318-675-7207</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System ( Site 1821)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>313-623-2531</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center ( Site 1846)</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>601-815-2756</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center ( Site 1835)</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>402-559-8609</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center ( Site 1850)</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>704-331-9669</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vidant Medical Center ( Site 1865)</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>252-847-4100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanford Health ( Site 1851)</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>701-234-6063</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Temple University ( Site 1836)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>215-707-1359</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRISTUS Institute for Innovation &amp; Advanced Clinical Care ( Site 1864)</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>321-917-9263</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital ( Site 1863)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>713-441-3250</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center ( Site 1812)</name>
      <address>
        <city>Edmonds</city>
        <state>Washington</state>
        <zip>98026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>206-234-2934</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Valley Medical Center ( Site 1815)</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>425-690-3503</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center ( Site 1861)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>206-215-2520</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chronos Pesquisa Clínica ( Site 0105)</name>
      <address>
        <city>Brasilia</city>
        <state>Distrito Federal</state>
        <zip>72145-424</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+556134917804</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Misericordia de Belo Horizonte ( Site 0100)</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30150-221</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+55 31 38790085</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas da Universidade Federal do Parana ( Site 0104)</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80060-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+554133601064</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Tacchini ( Site 0107)</name>
      <address>
        <city>Bento Goncalves</city>
        <state>Rio Grande Do Sul</state>
        <zip>95700-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+555434554333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>FUNFARME Hospital de Base Centro Integrado de Pesquisa ( Site 0101)</name>
      <address>
        <city>Sao Jose do Rio Preto</city>
        <state>Sao Paulo</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+551732015054</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Health Network - Toronto General Hospital ( Site 0201)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4163403871</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Fusat ( Site 0300)</name>
      <address>
        <city>Rancagua</city>
        <state>Libertador General Bernardo O Higgins</state>
        <zip>2820945</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>56989022206</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de los Andes ( Site 0301)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>2820945</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>562 2618 3100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sotero del Rio [Santiago, Chile] ( Site 0304)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>8207257</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56962392232</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario San Jose ( Site 0306)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>8380419</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56998170451</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Servicio de Salud Sur Hospital Lucio Cordova ( Site 0305)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>8900085</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+566008369000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Tobon Uribe ( Site 0404)</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050034</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5744459753</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica de la Costa Ltda. ( Site 0402)</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <zip>080020</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573128335766</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncomedica S.A. ( Site 0406)</name>
      <address>
        <city>Monteria</city>
        <state>Cordoba</state>
        <zip>230002</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5747854344</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Ignacio ( Site 0401)</name>
      <address>
        <city>Bogota</city>
        <state>Distrito Capital De Bogota</state>
        <zip>110231</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5715946161</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Cardiovascular de Colombia ( Site 0403)</name>
      <address>
        <city>Bucaramanca</city>
        <state>Santander</state>
        <zip>680003</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5776392744</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Valle del Lili ( Site 0400)</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760032</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5723319090</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pellegrin ( Site 0511)</name>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33556795679</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pitie Salpetriere University Hospital-Infectious Disease - Tropical Diseases ( Site 0504)</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33142160262</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>C.H.U. de Toulouse, Hopital de Purpan ( Site 0501)</name>
      <address>
        <city>Toulouse</city>
        <state>Midi-Pyrenees</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33561777508</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Tourcoing ( Site 0502)</name>
      <address>
        <city>Tourcoing</city>
        <state>Nord</state>
        <zip>59208</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33320694949</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Hopital Saint Antoine ( Site 0505)</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+331492833170</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Bichat - Claude Bernard ( Site 0503)</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33140257803</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center ( Site 2102)</name>
      <address>
        <city>Haifa</city>
        <zip>3525408</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+972502061980</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center. Ein Kerem ( Site 2103)</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97226779372</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center ( Site 2100)</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97235303500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital ( Site 2202)</name>
      <address>
        <city>Daejeon</city>
        <state>Taejon-Kwangyokshi</state>
        <zip>30515</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82422808369</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital ( Site 2204)</name>
      <address>
        <city>Incheon</city>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82328902548</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Eunpyeong St Mary s Hospital ( Site 2205)</name>
      <address>
        <city>Seoul</city>
        <zip>03312</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82220304341</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran ( Site 0802)</name>
      <address>
        <city>Ciudad de mexico</city>
        <state>Distrito Federal</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5554182965</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Regional de Alta Especialidad del Bajio ( Site 0807)</name>
      <address>
        <city>Leon</city>
        <state>Guanajuato</state>
        <zip>37660</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>524772672000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0800)</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+523330071046</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Jose Eleuterio Gonzalez ( Site 0803)</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+528112635696</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lung Center of the Philippines ( Site 0902)</name>
      <address>
        <city>Quezon City</city>
        <state>National Capital Region</state>
        <zip>1100</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+639178999610</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny im. dr. Wladyslawa Bieganskiego ( Site 1001)</name>
      <address>
        <city>Lodz-Baluty</city>
        <state>Lodzkie</state>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+42 251 61 99</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie ( Site 1004)</name>
      <address>
        <city>Lublin</city>
        <state>Lubelskie</state>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48602365317</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia, Mazowiecki Szpital Specjalistyczny, Oddział Obserwacyjno - Zakaźny ( Site 1</name>
      <address>
        <city>Ostroleka</city>
        <state>Mazowieckie</state>
        <zip>07-410</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+22 765 21 18</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne w Lancucie Sp.zo.o. ( Site 1000)</name>
      <address>
        <city>Lancut</city>
        <state>Podkarpackie</state>
        <zip>37-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48600491593</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krasnogorsk City Hospital Number 1 ( Site 1119)</name>
      <address>
        <city>Krasnogorsk</city>
        <state>Moskovskaya Oblast</state>
        <zip>143408</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74955631400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #40 ( Site 1109)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>108814</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74956838084</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>FSBI Central Hospital with Policlinics ( Site 1105)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>121359</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74955300111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moscow Clinical Hospital #52 ( Site 1103)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>123182</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74991963936</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>City Hospital #40 ( Site 1113)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>197706</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78124374075</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>City Pokrovskaya hospital ( Site 1116)</name>
      <address>
        <city>Saint-Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>199106</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78123220078</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #1 ( Site 1112)</name>
      <address>
        <city>Smolensk</city>
        <state>Smolenskaya Oblast</state>
        <zip>214006</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74812271011</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Infectious Hospital n.a. A.F. Agafonov ( Site 1100)</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan, Respublika</state>
        <zip>420140</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78432678117</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IATROS International ( Site 1202)</name>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27514440037</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wits Baragwanath Clinical Trial Site ( Site 1204)</name>
      <address>
        <city>Soweto</city>
        <state>Gauteng</state>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+28119836501</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Projects Research Centre ( Site 1205)</name>
      <address>
        <city>Worcester</city>
        <state>Western Cape</state>
        <zip>6850</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27233474485</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d Hebron ( Site 1305)</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluna</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34934894377</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic ( Site 1304)</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>34 93 2275708</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol ( Site 1303)</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>34934978849</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Maranon ( Site 1302)</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34915868000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal ( Site 1301)</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34913369100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz ( Site 1300)</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34912077384</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankivsk Regional Clinical Infectious Diseases Hospital ( Site 1605)</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <state>Ivano-Frankivska Oblast</state>
        <zip>76007</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+38-050-674-91-09</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CNE Central city clinical hospital of Ivano-Frankivsk city council ( Site 1604)</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <state>Ivano-Frankivska Oblast</state>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380990743476</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MNE Ivano-Frankivsk Regional Phthisiology-Pulmonology Center ( Site 1603)</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <state>Ivano-Frankivska Oblast</state>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380679796690</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CNPE of Kharkiv RC Regional Clinical Infectious Diseases Hospital ( Site 1606)</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>380996410027</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Сommunal non-com. Institution Oleksandrivska clinical hospital Kyiv ( Site 1600)</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>01601</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380677738141</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odesa City Clinical Infectious Hospital ( Site 1611)</name>
      <address>
        <city>Odesa</city>
        <state>Odeska Oblast</state>
        <zip>65023</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380487285550</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Non-Commercial Enterprise Central City Hospital ( Site 1615)</name>
      <address>
        <city>Rivne</city>
        <state>Rivnenska Oblast</state>
        <zip>33018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>80501475774</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Volyn Regional Clinical Hospital ( Site 1613)</name>
      <address>
        <city>Lutsk</city>
        <state>Volynska Oblast</state>
        <zip>43005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380505470790</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Free London NHS Foundation Trust ( Site 1700)</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>442077940500362850</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>King's College Hospital ( Site 1705)</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442032994015</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Manchester General Hospital ( Site 1701)</name>
      <address>
        <city>Manchester</city>
        <zip>M8 5RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>441619223429</phone>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>October 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

